Connect with us
DAPA Banner

Business

Olive Garden parent to close all Bahama Breeze restaurants

Published

on

Olive Garden parent to close all Bahama Breeze restaurants

Darden Restaurants announced on Tuesday that it will close its Bahama Breeze chain after nearly 30 years in operation.

The Orlando-based company said it will permanently shut down 14 of Bahama Breeze’s 28 restaurants, while converting the remaining locations into other Darden brands.

Advertisement

Restaurants designated for permanent closure will continue operating through April 5, Darden said.

RESTAURANT GIANT FILES FOR BANKRUPTCY UNDER MASSIVE DEBT SHORTLY AFTER TOUTING MAJOR EXPANSION

Signage is displayed outside of a Darden Restaurants Inc. Bahama Breeze Island Grille location in Schaumburg, Illinois, U.S., on Thursday, June 22, 2017. Darden Restaurants Inc. is scheduled to reporter earnings figures on June 27. Photographer: Daniel Acker/Bloomberg via Getty Images

Sign in front of a Darden Restaurants Inc. Bahama Breeze Island Grille in Schaumburg, Illinois, on June 22, 2017. (Daniel Acker/Bloomberg via Getty Images)

The conversion of the remaining 14 locations is expected to take 12 to 18 months. Those restaurants will continue operating until any temporary closures are required during the conversion process, the company said.

A vehicle sits parked outside of a Darden Restaurants Inc. Bahama Breeze Island Grille location in Schaumburg, Illinois, U.S., on Thursday, June 22, 2017. Darden Restaurants Inc. is scheduled to reporter earnings figures on June 27. Photographer: Daniel Acker/Bloomberg via Getty Images

A vehicle sits parked outside a Bahama Breeze restaurant in Schaumburg, Illinois, on June 22, 2017. (Daniel Acker/Bloomberg via Getty Images)

Darden did not specify which brands the Bahama Breeze locations will be converted into. The company’s portfolio includes chains such as Olive Garden, Yard House, Ruth’s Chris Steak House and Eddie V’s, among others.

Advertisement

THIS RESTAURANT IS THE BEST PLACE TO EAT IN THE US, ACCORDING TO YELP

“The company believes the conversion locations are great sites that will benefit several of the brands in its portfolio,” Darden said in a press release. “Going forward, the primary focus will continue to be on supporting team members, including placing as many as possible in roles within the Darden portfolio.”

Signage is displayed at a Darden Restaurants Inc. Bahama Breeze Island Grille location in Schaumburg, Illinois, U.S., on Thursday, June 22, 2017. Darden Restaurants Inc. is scheduled to reporter earnings figures on June 27. Photographer: Daniel Acker/Bloomberg via Getty Images

Most of the locations that will be converted into other brands are in Florida. (Daniel Acker/Bloomberg via Getty Images)

The Bahama Breeze locations slated for permanent closure are in Delaware, Georgia, Michigan, New Jersey, North Carolina, Pennsylvania, Virginia and Washington, Darden said.

CLICK HERE TO GET FOX BUSINESS ON THE GO

Advertisement

Most of the locations that will be converted into other brands are in Florida, with additional restaurants in Georgia, North Carolina, South Carolina and Virginia.

Shares of Darden Restaurants are up more than 14% year to date.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Selling Sheffield Wednesday

Published

on

Selling Sheffield Wednesday

BBC Sport looks at one of England’s most famous football clubs’ fight for survival.

Continue Reading

Business

Bentley workers 'shocked and angry' at job cuts

Published

on

Bentley workers 'shocked and angry' at job cuts

A union says the announcement came as a blow to employees with up to 275 positions at risk.

Continue Reading

Business

Icotyde psoriasis pill from J&J to rival Tremfya Skyrizi IL-23 shots

Published

on

Icotyde psoriasis pill from J&J to rival Tremfya Skyrizi IL-23 shots

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025.

Kyle Grillot | Bloomberg | Getty Images

Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots.

Advertisement

The FDA approved the pill, Icotyde, to treat moderate to severe plaque psoriasis, an autoimmune condition that causes rough patches of skin. Patients typically start treatment with topical medications.

If those don’t work, they advance to pills or shots. J&J sees Icotyde becoming the first-line systematic treatment for psoriasis, in between topicals and shots.

Drugmakers have been developing more advanced medicines than standard topicals, turning psoriasis into a highly competitive space. Icotyde targets the same IL-23 receptor as best-selling shots like J&J’s Tremfya and AbbVie‘s Skyrizi, giving patients an oral alternative to some of the most advanced — and most expensive — drugs on the market.

“To be able to to be able to have something that is relatively simple, that offers that level of clearance, trusted safety profile, and in a simple pill, we think is going to be revolutionary,” said Jennifer Taubert, chairman of J&J Innovative Medicine.

Advertisement

J&J estimates about 8 million people in the U.S. have plaque psoriasis, and that 75% of people don’t advance from topicals to shots because of reasons like fearing needles. Taubert sees Icotyde appealing to those patients.

“We believe having the type of profile that Icotyde has in a simple, once-daily oral pill, we think it’s going to be an absolute game changer for patients,” Taubert said.

J&J hasn’t announced how much Icotyde will cost beyond saying the company will help people pay for the medicine. Rival shots Tremfya and Skyrizi cost around $100,000 a year.

J&J sees peak annual sales of Icotyde exceeding $5 billion once it’s approved for other autoimmune conditions. It’s testing the drug for psoriatic arthritis, ulcerative colitis and Crohn’s disease.

Advertisement

Shares of J&J slid one-quarter of a percent Wednesday while shares of Skyrizi-maker AbbVie fell more than 4%. Protagonist Therapeutics, a biotech company that developed Icotyde with J&J, was trading about flat.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Continue Reading

Business

Brightstar Lottery stock hits 52-week low at 12.6 USD

Published

on


Brightstar Lottery stock hits 52-week low at 12.6 USD

Continue Reading

Business

Stocks Can’t Recover While Oil Prices Surge. Why the Fed’s Unlikely to Help.

Published

on

Stocks Can’t Recover While Oil Prices Surge. Why the Fed’s Unlikely to Help.

Stocks Can’t Recover While Oil Prices Surge. Why the Fed’s Unlikely to Help.

Continue Reading

Business

US holds interest rates as Iran war triggers oil shock

Published

on

US holds interest rates as Iran war triggers oil shock

The US central bank is moving cautiously, despite pressure from the president to cut interest rates.

Continue Reading

Business

Big Tech’s Huge Conglomerate Premium

Published

on

Big Tech’s Huge Conglomerate Premium

Big Tech’s Huge Conglomerate Premium

Continue Reading

Business

Datassential reveals top emerging foodservice chains

Published

on

Datassential reveals top emerging foodservice chains

Top chains specialized in focused concepts and tapped into trending flavors.

Continue Reading

Business

Hewlett Packard Enterprise's AI Story Moved To The Network Layer

Published

on

Hewlett Packard Enterprise's AI Story Moved To The Network Layer

Hewlett Packard Enterprise's AI Story Moved To The Network Layer

Continue Reading

Business

Iran’s military escalation backfiring, former Israeli general consul says

Published

on

Iran's military escalation backfiring, former Israeli general consul says

Iran’s latest military escalation is backfiring on the global stage as new strikes and widening regional fallout expose what a former Israeli consul general in New York called a critical miscalculation by Tehran.

Ambassador Ido Aharoni, who served as consul general of Israel in New York, joined FOX Business’ “Mornings With Maria” on Wednesday to discuss the broader implications of Iran’s recent actions and the shifting dynamics across the Middle East.

Advertisement
Iran flag in rubble and debris

An Iranian flag lies amid rubble and debris in Tehran. (Atta Kenare/AFP via Getty Images)

“Iran made a terrible mistake attacking Cyprus, thus bringing in the European Union,” Aharoni told host Maria Bartiromo.

He said Iran’s decision to expand its targets is drawing in new international pressure and raising concerns far beyond the region.

IRAN WAR UNLIKELY TO TRIGGER GLOBAL SUPPLY CHAIN CRISIS, GOLDMAN SACHS SAYS

“Iran is presenting a threat to the entire world,” Aharoni said.

Advertisement

The former consul general argued the U.S. and Israel’s ongoing military campaign is reshaping deterrence and exposing the regime’s vulnerabilities.

“For the first time since 1979, Iran is being punished for its motivation, for its ideology, not just for their actions… This sends a very powerful message throughout the region,” Aharoni said.

“This is how you restore deterrence… This is exactly what is being done.”

Advertisement

PRINCE REZA PAHLAVI HAS ‘MAJORITY SUPPORT’ AMONG IRANIANS AS PRESSURE BUILDS ON REGIME, CHIEF OF STAFF SAYS

He said Iran’s long-term position is weakening as a result of Operation Epic Fury. 

“They’re not going to be the same regional power that they were before or after this. It will take them decades to rebuild the infrastructure that was destroyed,” Aharoni explained.

Aharoni underscored that Iran’s actions are impacting its own population as instability grows.

“The Iranians are the number one victims of their own regime,” Aharoni said.

CLICK HERE TO GET FOX BUSINESS ON THE GO

Advertisement
Continue Reading

Trending

Copyright © 2025